急性淋巴细胞白血病中的增强子异质性驱动患者差异基因表达
本研究探讨急性淋巴细胞白血病(ALL)转录异质性的机制。研究发现新型增强子使用是ALL的常见特征,KMT2A::AFF1 ALL患者间转录异质性显著,单细胞多组学与染色质分析显示该异质性由新型增强子使用驱动,患者特异性增强子活性调控MEIS1和RUNX2等关键癌基因表达。
要点
- 新型增强子使用是急性淋巴细胞白血病(ALL)的常见特征
- KMT2A::AFF1 ALL患者间存在显著转录异质性
- 患者特异性增强子活性驱动MEIS1和RUNX2癌基因高表达
核心结论
- 增强子异质性在KMT2A::AFF1 ALL中高度普遍,可能是驱动癌症转录异质性的更普遍机制。
研究设计与样本
- 研究采用单细胞多组学分析和广泛染色质谱分析,并在原发患者样本中生成高分辨率Micro Capture-C数据;原文未报告样本量。
主要发现
- KMT2A::AFF1 ALL患者间表现出显著的转录异质性,其中大部分异质性由新型增强子使用驱动。
- 在MEIS1和RUNX2等关键癌基因处鉴定出患者特异性增强子活性,以患者特异性方式驱动这两个癌基因的高水平表达。
关键数值与推荐
- KMT2A::AFF1 ALL为侵袭性白血病,预后差且突变负荷低;原文未报告其他数值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Genetic alterations alone cannot account for the diverse phenotypes of cancer cells. Even cancers with the same driver mutation show significant transcriptional heterogeneity and varied responses to therapy. However, the mechanisms underpinning this heterogeneity remain underexplored. Here, we find that novel enhancer usage is a common feature in acute lymphoblastic leukemia (ALL). In particular, KMT2A::AFF1 ALL, an aggressive leukemia with a poor prognosis and a low mutational burden, exhibits substantial transcriptional heterogeneity between individuals. Using single-cell multiome analysis and extensive chromatin profiling, we reveal that much transcriptional heterogeneity in KMT2A::AFF1 ALL is driven by novel enhancer usage. By generating high-resolution Micro Capture-C data in primary patient samples, we identify patient-specific enhancer activity at key oncogenes such as MEIS1 and RUNX2, driving high levels of expression of both oncogenes in a patient-specific manner. Overall, our data show that enhancer heterogeneity is highly prevalent in KMT2A::AFF1 ALL and may be a mechanism that drives transcriptional heterogeneity in cancer more generally.
引用
- Smith AL, Denny N, Chahrour C, et al. Enhancer heterogeneity in acute lymphoblastic leukemia drives differential gene expression in patients. Blood. 2025. PMID: 40729681. doi:10.1182/blood.2024028019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。